Journal of Cancer Metastasis and Treatment最新文献_第3页

Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions. 剖析多发性骨髓瘤和前体疾病免疫微环境功能失调的分子机制。

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-05-16 DOI: 10.20517/2394-4722.2022.110

Maria Moscvin, Benjamin Evans, Giada Bianchi

{"title":"Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions.","authors":"Maria Moscvin, Benjamin Evans, Giada Bianchi","doi":"10.20517/2394-4722.2022.110","DOIUrl":"10.20517/2394-4722.2022.110","url":null,"abstract":"Multiple myeloma (MM) is a disease of clonally differentiated plasma cells. MM is almost always preceded by precursor conditions, monoclonal gammopathy of unknown significance (MGUS), and smoldering MM (SMM) through largely unknown molecular events. Genetic alterations of the malignant plasma cells play a critical role in patient clinical outcomes. Del(17p), t(4;14), and additional chromosomal alterations such as del(1p32), gain(1q) and MYC translocations are involved in active MM evolution. Interestingly, these genetic alterations appear strikingly similar in transformed plasma cell (PC) clones from MGUS, SMM, and MM stages. Recent studies show that effectors of the innate and adaptive immune response show marked dysfunction and skewing towards a tolerant environment that favors disease progression. The MM myeloid compartment is characterized by myeloid-derived suppressor cells (MDSCs), dendritic cells as well as M2-like phenotype macrophages that promote immune evasion. Major deregulations are found in the lymphoid compartment as well, with skewing towards immune tolerant Th17 and Treg and inhibition of CD8+ cytotoxic and CD4+ activated effector T cells. In summary, this review will provide an overview of the complex cross-talk between MM plasma cells and immune cells in the microenvironment and the molecular mechanisms promoting progression from precursor states to full-blown myeloma.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10783205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current diagnosis and management of cardiac melanoma: a case series and review 目前心脏黑色素瘤的诊断和治疗:一个病例系列和回顾

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.113

Aaron S. Long, Jung-Jung Chang, J. Glahn, K. Olino, Thuy T. Tran, James E. Clune

引用次数: 0

The role of pro-inflammatory components, carcinoma-associated fibroblasts, and tumor-associated macrophages in ovarian cancer progression and metastasis 促炎成分、癌相关成纤维细胞和肿瘤相关巨噬细胞在卵巢癌进展和转移中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.91

引用次数: 1

Treatment strategy after the discontinuation of immunotherapy for head and neck cancer: a review 头颈癌停止免疫治疗后的治疗策略综述

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.115

T. Wakasugi

{"title":"Treatment strategy after the discontinuation of immunotherapy for head and neck cancer: a review","authors":"T. Wakasugi","doi":"10.20517/2394-4722.2022.115","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.115","url":null,"abstract":"First-line systemic therapy with immune checkpoint inhibitors (ICIs) is currently the mainstream treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) that is not amenable to local therapy. However, the optimal treatment after discontinuation of ICIs is still unknown, and no large-scale analysis has been conducted in R/M SCCHN. In this narrative review, we summarize the treatment strategies available to continue ICI therapy using the currently available treatment modalities. After the administration of ICIs, unlike cytotoxic agents, the following responses are observed: durable response, pseudo-progressive disease, hyper-progressive disease, mixed response, immune-related adverse events (irAEs), and improved sensitivity to subsequent chemotherapy. Some patients show a durable response to ICIs and a good prognosis; however, many patients will require salvage therapy. We need to select the subsequent treatment according to the various responses unique to ICIs to obtain a durable response. For instance, there are reports on the effectiveness of reapplication of local therapy for a mixed response, retreatment with ICIs, and off-treatment in responsive cases complicated by irAEs. If a durable response can be maintained with ICI therapy, a long-term prognosis that cannot be obtained with conventional chemotherapy can be achieved.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The efficacy and safety of intramuscular aceclofenac and diclofenac for managing postoperative pain in patients undergoing composite resection for oral cancer 肌注乙酰氯芬酸和双氯芬酸治疗口腔癌复合切除术患者术后疼痛的疗效和安全性

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.84

引用次数: 0

Bio-fabrication of liver cancer stem cells and testing of gemcitabine 肝癌干细胞的生物制备及吉西他滨的试验

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.114

Evrim Cevik, O. Erdogan, O. Cevik

{"title":"Bio-fabrication of liver cancer stem cells and testing of gemcitabine","authors":"Evrim Cevik, O. Erdogan, O. Cevik","doi":"10.20517/2394-4722.2022.114","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.114","url":null,"abstract":"Aim: Cancer stem cells are cell populations that are essential in drug resistance and cancer metastasis. Some liver cancer cells exhibit the characteristics of cancer stem cells, and it is crucial to study the activities and interactions of drugs in these cells. Huh7 is a human liver cancer cell with stem cell biomarkers and is used with induced pluripotent stem cells to form various cancer organoids through encapsulation methods. Due to their ease of use without animal testing, bio-fabrication studies of cell-encapsulated models have gained importance in the pharmaceutical industry in recent years. This study aimed to biofabricate Huh7 human liver cancer stem cells by alginate encapsulation and test gemcitabine’s efficacy. Methods: Huh7 cells were encapsulated with alginate (0.8% w/v) and fibronectin, and their viability was evaluated with 3.2 µM gemcitabine on days 1, 3, 6, 9, and 12. Furthermore, gene expressions of stem cell markers CD90 and AFP were evaluated in encapsulated Huh7 cells by qPCR. In addition, IL-6 secretion in the cell medium was measured by ELISA for the tumor microenvironment. Results: Encapsulation of Huh7 cells was found to maintain their viability and stem cell properties for up to 12 days. In addition, alginate-encapsulated Huh7 cells were bio-fabricated to demonstrate long-term gemcitabine response. While the effect of the gemcitabine was evaluated in alginate-encapsulated Huh7 cells, CD90 and AFP mRNA levels were significantly reduced in the cells and IL-6 secretion was decreased in the tumor microenvironment. Conclusion: This study demonstrated that bio-fabrication of alginate-encapsulated Huh7 cells is a novel approach for long-term drug testing in liver cancer models. Bio-fabricated alginate-encapsulated cancer stem cells may be a cheaper and faster method for the testing of many drugs.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review on applications of metastatic lymph node based radiomic assessment in nasopharyngeal carcinoma 转移淋巴结放射学评估在鼻咽癌中的应用综述

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.100

引用次数: 0

The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas. 弥漫性胸膜间皮瘤患者靶向治疗方法的过去、现在和未来。

IF 1.4

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-05-30 DOI: 10.20517/2394-4722.2022.140

Michael Offin, Bailey Fitzgerald, Marjorie G Zauderer, Deborah Doroshow

引用次数: 0

Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? 两种罕见的外分泌胰腺癌:像导管腺癌一样治疗还是不治疗?

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.106

Nebojsa Skorupan, Shadin Ghabra, J Alberto Maldonado, Yang Zhang, Christine Alewine

{"title":"Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?","authors":"Nebojsa Skorupan, Shadin Ghabra, J Alberto Maldonado, Yang Zhang, Christine Alewine","doi":"10.20517/2394-4722.2022.106","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.106","url":null,"abstract":"Pancreatic cancer is an aggressive malignancy with increasing incidence. Pancreatic ductal adenocarcinoma (PDAC) accounts for > 90% of pancreatic cancer diagnoses, while other exocrine tumors are much rarer. In this review, we have focused on two rare cancers of the exocrine pancreas: adenosquamous carcinoma of the pancreas (ASCP) and pancreatic acinar cell carcinoma (PACC). The latest findings regarding their cellular and molecular pathology, clinical characteristics, prognosis, and clinical management are discussed. New genetic and transcriptomic data suggest that ASCP is related to or overlaps with the basal transcriptomic subtype of PDAC. These tumors are highly aggressive and driven by activated KRAS and MYC expression. Clinical outcomes remain poor and effective treatments are limited. PACC has no morphologic or genetic resemblance to PDAC and more favorable outcomes. Early stage PACC patients have improved survival with surgical resection and patients with advanced disease benefit most from platinum- or fluoropyrimidine-containing chemotherapy. Frequency of actionable genetic mutations is high in this disease and case reports suggest good outcomes when matched therapy is given. Dedicated clinical studies examining ASCP and PACC are limited and difficult to accrue. Further research is needed to define optimal clinical management for these rare diseases.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Role of epithelial-mesenchymal transition factor SNAI1 and its targets in ovarian cancer aggressiveness. 上皮-间质转化因子SNAI1及其靶点在卵巢癌侵袭性中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-06-30 DOI: 10.20517/2394-4722.2023.34

Tise Suzuki, Ashlyn Conant, Casey Curow, Audrey Alexander, Yevgeniya Ioffe, Juli J Unternaehrer

引用次数: 1